Sanofi, Lilly, Novo and a trio of PBMs face racketeering claims over pricey insulin drugs
July 14, 2021
Sanofi, Lilly, Novo and a trio of PBMs face racketeering claims over pricey insulin drugs. Reportedly, Sanofi is pleased that the court has narrowed the claims at issue.
fkansteiner Tue, 07/13/2021 – 11:36
Read the source article at Pharma News
2021-07-13 15:13:13